These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 31632022

  • 1. Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy.
    Ma Y, Yuwen D, Chen J, Zheng B, Gao J, Fan M, Xue W, Wang Y, Li W, Shu Y, Xu Q, Shen Y.
    Int J Nanomedicine; 2019; 14():8121-8132. PubMed ID: 31632022
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
    Yuwen D, Ma Y, Wang D, Gao J, Li X, Xue W, Fan M, Xu Q, Shen Y, Shu Y.
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.
    Tian W, Yang X, Yang H, Lv M, Sun X, Zhou B.
    Cell Death Dis; 2021 Oct 30; 12(11):1030. PubMed ID: 34718336
    [Abstract] [Full Text] [Related]

  • 9. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
    Deng SH, Wu DM, Li L, Liu T, Zhang T, Li J, Yu Y, He M, Zhao YY, Han R, Xu Y.
    Biochem Biophys Res Commun; 2021 Apr 16; 549():54-60. PubMed ID: 33662669
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B, Hu N, Cong D, Chen K, Li J.
    Bioengineered; 2021 Dec 16; 12(1):3219-3228. PubMed ID: 34266345
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM, Ge F, Chen XJ, Tang C, Ma J.
    Eur Rev Med Pharmacol Sci; 2019 Jun 16; 23(12):5242-5250. PubMed ID: 31298375
    [Abstract] [Full Text] [Related]

  • 13. Up-regulation of microRNA miR-101-3p enhances sensitivity to cisplatin via regulation of small interfering RNA (siRNA) Anti-human AGT4D and autophagy in non-small-cell lung carcinoma (NSCLC).
    Cui D, Feng Y, Qian R.
    Bioengineered; 2021 Dec 16; 12(1):8435-8446. PubMed ID: 34694211
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
    Huang G, Lou T, Pan J, Ye Z, Yin Z, Li L, Cheng W, Cao Z.
    Aging (Albany NY); 2019 Apr 12; 11(7):2138-2150. PubMed ID: 30981205
    [Abstract] [Full Text] [Related]

  • 17. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
    Xing S, Qu Y, Li C, Huang A, Tong S, Wu C, Fan K.
    J Cell Physiol; 2019 Dec 12; 234(12):22657-22665. PubMed ID: 31111480
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
    Hu B, Zhang H, Wang Z, Zhang F, Wei H, Li L.
    Cancer Biol Ther; 2017 Dec 02; 18(12):974-983. PubMed ID: 29020498
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.